These treatments have not been shown to be effective for solid tumors and continue to exhibit a relatively high rate of adverse effects and toxicities, including cytokine release syndrome (CRS ...

Their study has also shown that the release of CRS-relevant cytokines is independent of the presence of tumor cells. Instead, ...

Dr. Koffman has had no major side effects since the first five weeks of the trial when researchers were still figuring out the proper dosage and countering cytokine release syndrome (CRS ...

showing promise without inducing cytokine release syndrome (CRS) in participants. TuHURA's President and CEO, James Bianco, M.D., emphasized the potential of KVA12123 to improve treatment ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD ...

All doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome scores POLB 001 treatment showed statistically significant reductions in key cytokines Positive results ...

KVA12123 is a VISTA-blocking immunotherapy in development as a monoclonal ... models or induction of cytokine release syndrome (CRS) in human clinical trials. Through the combination of unique ...

KVA12123 is a VISTA-blocking immunotherapy in development as a monoclonal ... inhibition in preclinical models without evidence of CRS in clinical trial participants. KVA12123 has been shown ...